Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold) and Lilly (Silver).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

IBC 2024 | Richter’s transformation: biology & ongoing trials in the field

Carsten Niemann, Erin Parry and Matthew Davids • 25 Mar 2024
IBC 2024
Chronic Lymphocytic Leukemia Leukemia BTK inhibitors

In this discussion, Matthew Davids, MD, Dana-Farber Cancer Institute, Boston, MA, Erin Parry, MD, PhD, Dana-Farber Cancer Institute, Boston, MA, and Carsten Niemann, MD, PhD, Copenhagen University Hospital, Copenhagen, Denmark, discuss updates in the biology of Richter’s transformation (RT), commenting on the impact of novel targeted agents in this space. The experts further highlight exciting clinical trials emerging for patients, including those exploring the use of bispecific antibodies. This session was filmed at IBC 2024, held in Lisbon, Portugal.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Carsten Niemann

Second-line treatment in CLL after venetoclax-based frontline: insights from GAIA/CLL13 and CLL17
5:20
Second-line treatment in CLL after venetoclax-based frontline: insights from GAIA/CLL13 and CLL17
Carsten Niemann • 5 Dec 2025
Preventing infectious complications in patients with CLL: vaccination and social behaviors
3:43
Preventing infectious complications in patients with CLL: vaccination and social behaviors
Carsten Niemann • 5 Dec 2025
Data-driven hematology: next steps in the implementation of the CLL treatment infection model
3:30
Data-driven hematology: next steps in the implementation of the CLL treatment infection model
Carsten Niemann • 5 Dec 2025
The PreVent-ACaLL trial: treating patients with CLL who are at high risk of infections
2:55
The PreVent-ACaLL trial: treating patients with CLL who are at high risk of infections
Carsten Niemann • 7 Dec 2024

More from Erin Parry

Richter’s transformation in 2026: where does the field stand and what challenges remain?
1:24
Richter’s transformation in 2026: where does the field stand and what challenges remain?
Erin Parry • 17 Oct 2026
Improving the understanding of the genetics and biology underlying Richter's transformation
0:49
Improving the understanding of the genetics and biology underlying Richter's transformation
Erin Parry • 13 Sep 2025
Using disease profiling to identify potential therapeutic targets in Richter's transformation
1:01
Using disease profiling to identify potential therapeutic targets in Richter's transformation
Erin Parry • 13 Sep 2025
Treatment strategies under investigation for Richter's transformation
0:40
Treatment strategies under investigation for Richter's transformation
Erin Parry • 7 Oct 2023

More from Matthew Davids

Insights into the current CLL treatment algorithm and emerging research directions
1:51
Insights into the current CLL treatment algorithm and emerging research directions
Matthew Davids • 17 Oct 2026
Does MRD-guided therapy have potential in CLL?
1:01
Does MRD-guided therapy have potential in CLL?
Matthew Davids • 12 Jun 2026
Emerging treatments for patients with CLL previously exposed to BTK inhibitors and venetoclax
1:11
Emerging treatments for patients with CLL previously exposed to BTK inhibitors and venetoclax
Matthew Davids • 12 Jun 2026
GLORA trial: lisaftoclax plus BTKi in previously treated CLL
1:18
GLORA trial: lisaftoclax plus BTKi in previously treated CLL
Matthew Davids • 12 Jun 2026

Related Videos

Unmet needs in CLL genomics: heterogeneity and clinical impact
1:11
Unmet needs in CLL genomics: heterogeneity and clinical impact
Elias Campo • 16 Oct 2026
Insights into key topics most likely to impact day-to-day CLL management
1:40
Insights into key topics most likely to impact day-to-day CLL management
Alessandra Ferrajoli • 16 Oct 2026
Translating current CLL evidence into national guidelines: which gaps remain?
3:33
Translating current CLL evidence into national guidelines: which gaps remain?
Mary Ann Anderson • 16 Oct 2026
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
2:40
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
Philip Thompson • 22 Oct 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals